FDA Determines Regulatory Review Period for CRESEMBA Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of CRESEMBA, a new drug approved under the FDA's application number 207500, following a request from the US Patent and Trademark Office (USPTO) for an extension of the patent claiming the human drug product approved under NDA 207500.